We are live on ! Find out more
PCSA icon

Processa Pharmaceuticals
PCSA

16 hedge funds and large institutions have $6.47M invested in Processa Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 16 → 16 (0)

0% less ownership

Funds ownership: 0.02% → 0.02% (-0%)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

47% less capital invested

Capital invested by funds: $12.2M → $6.47M (-$5.75M)

60% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 5

Holders
16
Holders Change
–
Holders Change %
0%
% of All Funds
0.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
5
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CBA
Coastal Bridge Advisors
Connecticut
+$31K
2
BlackRock
BlackRock
New York
+$21.7K
3
TRCT
Tower Research Capital (TRC)
New York
+$9.3K
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$6.2K

Top Sellers

Rank Fund Capital Flow
1
ACM
AIGH Capital Management
Maryland
-$517K
2
WVP
Worth Venture Partners
New Jersey
-$124K
3
VCA
Verdence Capital Advisors
Maryland
-$68.2K
4
EIM
Essex Investment Management
Massachusetts
-$9.3K
5
HWA
Heritage Wealth Advisors
Virginia
-$8.57K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$1.83M -$3.1K -1 -0.1%
ACM
2
AIGH Capital Management
Maryland
$1.49M -$517K -167 -22%
SCM
3
Solas Capital Management
Connecticut
$961K – – –
EIM
4
Essex Investment Management
Massachusetts
$359K -$9.3K -3 -2%
WVP
5
Worth Venture Partners
New Jersey
$348K -$124K -40 -22%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$318K – – –
VCA
7
Verdence Capital Advisors
Maryland
$310K -$68.2K -22 -15%
Janney Montgomery Scott
8
Janney Montgomery Scott
Pennsylvania
$227K – – –
State Street
9
State Street
Massachusetts
$203K – – –
CBA
10
Coastal Bridge Advisors
Connecticut
$159K +$31K +10 +18%
BlackRock
11
BlackRock
New York
$149K +$21.7K +7 +13%
Northern Trust
12
Northern Trust
Illinois
$75K – – –
VRM
13
Vectors Research Management
New York
$20K – – –
AF
14
Allworth Financial
California
$8K – – –
TRCT
15
Tower Research Capital (TRC)
New York
$8K +$9.3K +3 New
Royal Bank of Canada
16
Royal Bank of Canada
Ontario, Canada
$5K +$6.2K +2 New
UBS Group
17
UBS Group
Switzerland
$1K -$3.1K -1 Closed
HWA
18
Heritage Wealth Advisors
Virginia
– -$8.57K -2 Closed
Morgan Stanley
19
Morgan Stanley
New York
– -$1K – –

PCSA Hedge Fund Activity: Q4 2021 in Review

16 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Processa Pharmaceuticals (PCSA) for Q4 2021, worth a combined $6.47M — down 47% from $12.2M a quarter earlier.

Fund positioning in PCSA was balanced in Q4 2021: 2 funds opened new positions, 2 closed out, 2 added to existing stakes and 5 trimmed.

The largest buyer was Coastal Bridge Advisors, adding an estimated $31K. The largest seller was AIGH Capital Management, cutting an estimated $517K.

  • 16 institutional investors held Processa Pharmaceuticals (PCSA) as of Q4 2021, unchanged from Q3 2021.
  • Funds reported $6.47M of Processa Pharmaceuticals stock for Q4 2021, down 47% quarter-over-quarter.
  • 2 funds opened new Processa Pharmaceuticals positions in Q4 2021 and 2 closed out, a net change of 0 holders.
  • The largest Processa Pharmaceuticals buyer in Q4 2021 was Coastal Bridge Advisors, an estimated $31K added.
  • The largest Processa Pharmaceuticals seller in Q4 2021 was AIGH Capital Management, an estimated $517K sold.

Based on aggregated 13F filings for Q4 2021.